GCTK · GlucoTrack Inc. Common Stock
View on chartInsiders & Stakes
| Drew Sycoff Director | ▲ Buy | Open Market | 2,951,258 Shares held | 4/22/2024 | View profile |
| John A. Ballantyne Revocable Living Trust dated 08/01/2017 10% Owner | ▼ Sell | Other | 2,743,591 Shares held | 3/12/2025 | View profile |
| Avner Gal Chairman and CEO | ▼ Sell | Other | 273,989 Shares held | 3/11/2015 | View profile |
| Zvi Cohen Director | ▼ Sell | Other | 241,625 Shares held | 3/11/2015 | View profile |
| David Malka Vice President of Operations | ▼ Sell | Other | 123,695 Shares held | 3/11/2015 | View profile |
| Andrew K. Balo * | ▲ Buy | Grant | 4,692 Shares held | 10/3/2025 | View profile |
| Angela Strand Boydston Director | ▲ Buy | Grant | 4,445 Shares held | 3/20/2017 | View profile |
| John Ballantyne Director | ▲ Buy | Grant | 4,126 Shares held | 3/26/2025 | View profile |
| Luis Malave Director | ▲ Buy | Grant | 4,058 Shares held | 10/3/2025 | View profile |
| Leslie Seff Director | ▲ Buy | Grant | 3,334 Shares held | 3/20/2017 | View profile |
| Erin Catherine Carter Director | ▲ Buy | Grant | 2,148 Shares held | 10/3/2025 | View profile |
| Robert Fischell Director | ▲ Buy | Grant | 2,045 Shares held | 3/26/2025 | View profile |
| Allen Danzig Director | ▲ Buy | Grant | 1,922 Shares held | 3/26/2025 | View profile |
| Paul Goode Chief Executive Officer | ▼ Sell | Other | 339 Shares held | 3/25/2025 | View profile |
Transaction History
| Erin Catherine Carter | ▲ Buy | Grant | 386 | $0 | 10/3/2025 |
| Luis Malave | ▲ Buy | Grant | 463 | $0 | 10/3/2025 |
| Andrew K. Balo | ▲ Buy | Grant | 1,285 | $0 | 10/3/2025 |
| Erin Catherine Carter | ▲ Buy | Grant | 1,000 | $0 | 7/11/2025 |
| Andrew K. Balo | ▲ Buy | Grant | 3,332 | $0 | 7/11/2025 |
| Luis Malave | ▲ Buy | Grant | 1,200 | $0 | 7/11/2025 |
| Robert Fischell | ▲ Buy | Grant | 1,498 | $0 | 3/26/2025 |
| Luis Malave | ▲ Buy | Grant | 2,076 | $0 | 3/26/2025 |
| Erin Catherine Carter | ▲ Buy | Grant | 1,896 | $0 | 3/26/2025 |
| Allen Danzig | ▲ Buy | Grant | 1,498 | $0 | 3/26/2025 |
| Andrew K. Balo | ▲ Buy | Grant | 4,490 | $0 | 3/26/2025 |
| John Ballantyne | ▲ Buy | Grant | 4,126 | $0 | 3/26/2025 |
| Luis Malave | ▲ Buy | Grant | 35 | $0 | 3/25/2025 |
| Paul Goode | ▼ Sell | Other | 42 | — | 3/25/2025 |
| Erin Catherine Carter | ▲ Buy | Grant | 32 | $0 | 3/25/2025 |
| Andrew K. Balo | ▲ Buy | Grant | 75 | $0 | 3/25/2025 |
| John A. Ballantyne Revocable Living Trust dated 08/01/2017 | ▼ Sell | Other | 2,560,553 | $0 | 3/12/2025 |
| Luis Malave | ▼ Sell | Other | 133,532 | $0 | 3/12/2025 |
| Erin Catherine Carter | ▼ Sell | Other | 40,297 | $0 | 3/12/2025 |
| Paul Goode | ▼ Sell | Other | 15,435 | $0 | 3/12/2025 |
| John Ballantyne | ▼ Sell | Other | 2,560,553 | $0 | 3/12/2025 |
| Paul Goode | ▼ Sell | Other | 1,500 | — | 2/5/2025 |
| John A. Ballantyne Revocable Living Trust dated 08/01/2017 | ▼ Sell | Other | 132,036 | $4.1M | 11/14/2024 |
| John Ballantyne | ▼ Sell | Other | 132,036 | $4.1M | 11/14/2024 |
| Erin Catherine Carter | ▼ Sell | Other | 2,078 | $65K | 11/14/2024 |
| Paul Goode | ▼ Sell | Other | 796 | $25K | 11/14/2024 |
| Luis Malave | ▼ Sell | Other | 6,886 | $215K | 11/14/2024 |
| Drew Sycoff | ▲ Buy | Open Market | 182,540 | $230K | 4/22/2024 |
| Luis Malave | ▲ Buy | Grant | 489 | $0 | 4/8/2024 |
| Erin Catherine Carter | ▲ Buy | Grant | 458 | $0 | 4/8/2024 |
| Robert Fischell | ▲ Buy | Grant | 229 | $0 | 4/8/2024 |
| Allen Danzig | ▲ Buy | Grant | 229 | $0 | 4/8/2024 |
| Erin Catherine Carter | ▲ Buy | Grant | 903 | $0 | 12/31/2023 |
| Luis Malave | ▲ Buy | Grant | 362 | $0 | 12/31/2023 |
| Luis Malave | ▲ Buy | Grant | 121 | $0 | 4/20/2023 |
| Luis Malave | ▲ Buy | Grant | 29 | $0 | 1/9/2023 |
| Luis Malave | ▲ Buy | Grant | 44 | $0 | 10/4/2022 |
| Allen Danzig | ▲ Buy | Grant | 44 | $0 | 10/4/2022 |
| Luis Malave | ▲ Buy | Grant | 34 | $0 | 6/30/2022 |
| Luis Malave | ▲ Buy | Grant | 25 | $0 | 3/31/2022 |
| Luis Malave | ▲ Buy | Grant | 11 | $0 | 12/31/2021 |
| Luis Malave | ▲ Buy | Grant | 8 | $0 | 9/30/2021 |
| Robert Fischell | ▲ Buy | Grant | 318 | $0 | 8/24/2021 |
| Angela Strand Boydston | ▲ Buy | Grant | 13,334 | $0 | 3/20/2017 |
| Angela Strand Boydston | ▲ Buy | Grant | 4,445 | $0 | 3/20/2017 |
| Leslie Seff | ▲ Buy | Grant | 3,334 | $0 | 3/20/2017 |
| Zvi Cohen | ▼ Sell | Other | 120,077 | $0 | 3/11/2015 |
| David Malka | ▼ Sell | Other | 61,471 | $0 | 3/11/2015 |
| Avner Gal | ▼ Sell | Other | 136,162 | $0 | 3/11/2015 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GCTK’s Lōkahi Expands Collaboration & Launches Qare
Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.
GCTK’s Lōkahi Expands Collaboration & Launches Qare. Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.